Bellevue Group’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q1
Sell
-4,460,693
Closed -$24.2M 163
2024
Q4
$24.2M Hold
4,460,693
0.47% 52
2024
Q3
$32.2M Sell
4,460,693
-4,000
-0.1% -$28.9K 0.52% 59
2024
Q2
$48.5M Sell
4,464,693
-851
-0% -$9.24K 0.79% 31
2024
Q1
$83.7M Buy
4,465,544
+952,193
+27% +$17.8M 1.28% 22
2023
Q4
$76.1M Hold
3,513,351
1.16% 25
2023
Q3
$72.3M Buy
3,513,351
+398,976
+13% +$8.21M 1.16% 24
2023
Q2
$146M Buy
3,114,375
+24,375
+0.8% +$1.15M 2.09% 11
2023
Q1
$130M Buy
3,090,000
+120,722
+4% +$5.07M 1.88% 13
2022
Q4
$113M Sell
2,969,278
-1,400
-0% -$53.4K 1.5% 19
2022
Q3
$116M Sell
2,970,678
-2,500
-0.1% -$97.9K 1.67% 14
2022
Q2
$96M Sell
2,973,178
-79,226
-3% -$2.56M 1.36% 17
2022
Q1
$101M Sell
3,052,404
-175,600
-5% -$5.81M 1.17% 28
2021
Q4
$137M Buy
3,228,004
+19,000
+0.6% +$808K 1.42% 20
2021
Q3
$142M Buy
3,209,004
+844,800
+36% +$37.4M 1.44% 17
2021
Q2
$134M Buy
2,364,204
+553,500
+31% +$31.4M 1.31% 20
2021
Q1
$136M Buy
1,810,704
+243,200
+16% +$18.2M 1.43% 18
2020
Q4
$136M Sell
1,567,504
-12,000
-0.8% -$1.04M 1.55% 17
2020
Q3
$96.5M Buy
1,579,504
+164,000
+12% +$10M 1.33% 20
2020
Q2
$58.9M Sell
1,415,504
-2,600
-0.2% -$108K 0.83% 33
2020
Q1
$40.7M Buy
1,418,104
+109,250
+8% +$3.14M 0.79% 36
2019
Q4
$94.5M Buy
1,308,854
+5,350
+0.4% +$386K 1.5% 19
2019
Q3
$183M Sell
1,303,504
-17,900
-1% -$2.51M 3.4% 5
2019
Q2
$242M Buy
1,321,404
+1,305,104
+8,007% +$239M 4.13% 5
2019
Q1
$2.59M Buy
16,300
+5,700
+54% +$907K 0.14% 99
2018
Q4
$1.02M Sell
10,600
-600
-5% -$57.5K 0.07% 114
2018
Q3
$1.58M Sell
11,200
-900
-7% -$127K 0.1% 110
2018
Q2
$1.89M Sell
12,100
-350
-3% -$54.8K 0.16% 91
2018
Q1
$2.01M Sell
12,450
-200
-2% -$32.2K 0.2% 79
2017
Q4
$2.08M Buy
+12,650
New +$2.08M 0.22% 76